Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR3 | P49019 | 3/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.49 |
| ▸ | RPS6KA1 | Q15418 | 2/20 | 0.49 |
| ▸ | ABL1 | P00519 | 3/20 | 0.47 |
| ▸ | HPGDS | O60760 | 2/20 | 0.47 |
| ▸ | CCNE1 | P24864 | 5/20 | 0.46 |
| ▸ | CDK2 | P24941 | 5/20 | 0.46 |
| ▸ | GSK3B | P49841 | 3/20 | 0.42 |
| ▸ | DYRK1A | Q13627 | 3/20 | 0.42 |
| ▸ | WNT1 | P04628 | 2/20 | 0.42 |
| ▸ | BRAF | P15056 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15511646 | 0.93 | MAPK1 (0.55) | HCAR3MAPK1RPS6KA1ABL1HPGDS | |
| SCHEMBL15511824 | 0.84 | MAPK1 (0.43) | HCAR3MAPK1RPS6KA1ABL1GSK3B | |
| SCHEMBL15551934 | 0.78 | HCAR3 (0.54) | HCAR3MAPK1RPS6KA1HPGDSGSK3B | |
| SCHEMBL15551931 | 0.78 | HCAR3 (0.54) | HCAR3MAPK1RPS6KA1HPGDSGSK3B | |
| SCHEMBL15583701 | 0.78 | HCAR3 (0.54) | HCAR3MAPK1RPS6KA1HPGDSGSK3B | |
| SCHEMBL17914055 | 0.77 | MAPK1 (0.68) | MAPK1RPS6KA1ABL1CCNE1CDK2 | |
| SCHEMBL30115216 | 0.76 | HCAR3 (0.54) | HCAR3 | |
| SCHEMBL15496252 | 0.75 | MAPK1 (0.65) | MAPK1RPS6KA1ABL1HPGDSCCNE1 | |
| SCHEMBL15498969 | 0.75 | MAPK1 (0.69) | MAPK1RPS6KA1CCNE1CDK2 | |
| SCHEMBL15496290 | 0.74 | MAPK1 (0.65) | MAPK1RPS6KA1ABL1HPGDSCCNE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2888247-B1 | SERINE/THREONINE KINASE INHIBITORS FOR THE TREATMENT OF HYPERPROLIFERATIVE DISEASES | ARRAY BIOPHARMA INC (US) | 2020-03-25 | — | — | EP | disclosed |
| US-9388171-B2 | Serine/threonine kinase inhibitors | GENETECH, INC. (US) | 2016-07-12 | — | — | US | disclosed |
| EP-2888247-A1 | SERINE/THREONINE KINASE INHIBITORS FOR THE TREATMENT OF HYPERPROLIFERATIVE!DISEASES | Array Biopharma, Inc. (US) | 2015-07-01 | — | — | EP | disclosed |
| US-20140066453-A1 | SERINE/THREONINE KINASE INHIBITORS | GENENTECH, INC. (US) | 2014-03-06 | — | — | US | disclosed |
| WO-2014036015-A1 | SERINE/THREONINE KINASE INHIBITORS FOR THE TREATMENT OF HYPERPROLIFERATIVE|DISEASES | ARRAY BIOPHARMA INC. (US) | 2014-03-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140066453-A1 | SERINE/THREONINE KINASE INHIBITORS | MAP3K1, MAP3K2, MAP3K20 | HCAR3 4284/4885MAPK1 28/4885RPS6KA1 98/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.